The rate of KRAS, BRAF, and NRAS mutations in our study population of relapsed disease patients (33%) is less than that found in series of unselected patients (around 50%),10 raising the possibility that patients with MAPK wild-type tumours could be selected for in this study. This evidence concerns the gene NRAS and neoplasm.